cyclic-gmp has been researched along with 4-amino-3-phenylbutyric-acid* in 2 studies
2 other study(ies) available for cyclic-gmp and 4-amino-3-phenylbutyric-acid
Article | Year |
---|---|
Inhibition of the Expression of Inducible NO Synthase by Neuroactive Amino Acid Derivatives Phenibut and Glufimet In Vitro and Ex Vivo.
Topics: Animals; Animals, Outbred Strains; Anti-Inflammatory Agents; Cyclic GMP; gamma-Aminobutyric Acid; Gene Expression; Glutamic Acid; Injections, Intraperitoneal; Lipopolysaccharides; Macrophage Activation; Macrophages, Peritoneal; Male; Mice; Nitrates; Nitric Oxide; Nitric Oxide Synthase Type II; Nitrites; Primary Cell Culture | 2017 |
Cyclic GMP protein kinase activity is reduced in thyroxine-induced hypertrophic cardiac myocytes.
1. We tested the hypothesis that the cGMP-dependent protein kinase has major negative functional effects in cardiac myocytes and that the importance of this pathway is reduced in thyroxine (T4; 0.5 mg/kg per day for 16 days) hypertrophic myocytes. 2. Using isolated ventricular myocytes from control (n = 7) and T4-treated (n = 9) rabbit hypertrophic hearts, myocyte shortening was studied with a video edge detector. Oxygen consumption was measured using O2 electrodes. Protein phosphorylation was measured autoradiographically. 3. Data were collected following treatment with: (i) 8-(4-chlorophenylthio)guanosine-3',5'-monophosphate (PCPT; 10-7 or 10-5 mol/L); (ii) 8-bromo-cAMP (10-5 mol/L) followed by PCPT; (iii) beta-phenyl-1,N2-etheno-8-bromoguanosine-3',5'-monophosphorothioate, SP-isomer (SP; 10-7 or 10-5 mol/L); or (iv) 8-bromo-cAMP (10-5 mol/L) followed by SP. 4. There were no significant differences between groups in baseline percentage shortening (Pcs; 4.9 +/- 0.2 vs 5.6 +/- 0.4% for control and T4 groups, respectively) and maximal rate of shortening (Rs; 64.8 +/- 5.9 vs 79.9 +/- 7.1 micro m/ s for control and T4 groups, respectively). Both SP and PCPT decreased Pcs (-43 vs-21% for control and T4 groups, respectively) and Rs (-36 vs-22% for control and T4 groups, respectively), but the effect was significantly reduced in T4 myocytes. 8-Bromo-cAMP similarly increased Pcs (28 vs 23% for control and T4 groups, respectively) and Rs (20 vs 19% for control and T4 groups, respectively). After 8-bromo-cAMP, SP and PCPT decreased Pcs (-34%) and Rs (-29%) less in the control group. However, the effects of these drugs were not altered in T4 myocytes (Pcs -24%; Rs -22%). Both PCPT and cAMP phosphorylated the same five protein bands. In T4 myocytes, these five bands were enhanced less. 5. We conclude that, in control ventricular myocytes, the cGMP-dependent protein kinase exerted major negative functional effects but, in T4-induced hypertrophic myocytes, the importance of this pathway was reduced and the interaction between cAMP and the cGMP protein kinase was diminished. Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Body Weight; Cyclic AMP; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Drug Administration Schedule; Drug Synergism; gamma-Aminobutyric Acid; Guanosine; Heart Ventricles; Hypertrophy; Injections, Intramuscular; Myocardial Contraction; Myocytes, Cardiac; Organ Size; Oxygen Consumption; Phosphoproteins; Phosphorylation; Rabbits; Stimulation, Chemical; Thyroxine; Time Factors | 2003 |